ATHX
Athersys, Inc.
Set alert
0.01 USD 0.00 0.00%
0.0116 Day range 0.0212
0.0045 52-week range 1.99
- Open
- 0.0177
- Prev close
- 0.0135
- Mkt cap
- 0
- Vol
- 6.46M
- Avg vol
- 1.77M
- EPS
- -1.65
- P/E
- -0.01
- Div yield
- 0.00%
More statistics
- Low
- 0.0116
- High
- 0.0212
- Forward P/E
- 0.00
- Beta
- 0.00
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 16, 2023
- 50-d avg
- 0.00
- 200-d avg
- 0.00
Key statistics
- Market cap
- 0
- Trailing P/E
- 0.00
- Forward P/E
- 0.00
- Price / sales
- 0.00
- Beta
- 0.00
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- 50-day average
- 0.00
- 200-day average
- 0.00
Next earnings
Nov 16, 2023
Expected Nov 16, 2023. Consensus EPS estimate 0.00.
Financials — quick view
ATHX Revenue — quarterly 49.00K
ATHX Net income — quarterly -12.92M
ATHX EPS — quarterly -0.62
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 16, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 16, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 15, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 31, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
| Nov 14, 2022 | Sep 1, 2022 | -1.96 | — | — | — |
| Aug 11, 2022 | Jun 1, 2022 | -1.75 | — | — | — |
News
- Head-To-Head Review: Athersys (NASDAQ:ATHX) versus Turn Therapeutics (NASDAQ:TTRX)
- Head-To-Head Analysis: Merck KGaA (OTCMKTS:MKGAF) vs. Athersys (NASDAQ:ATHX)
- Athersys (NASDAQ:ATHX) and Galera Therapeutics (NASDAQ:GRTX) Critical Review
- Athersys Reports Third Quarter 2023 Financial Results and Business Highlights
- Are Longevity Stocks the Next Trillion-Dollar Industry? 3 Anti-Aging Picks
- Why ServisFirst Bancshares Shares Are Trading Lower By 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
- Athersys Extends Near Term Liquidity with Proceeds from Warrant Inducement and Global ARDS License with Healios to Explore Strategic Alternatives
- Why Astra Space Shares Are Trading Lower By 22%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- Athersys Reports Interim Analysis Results of MASTERS-2 Clinical Study with MultiStem in Ischemic Stroke, Signs Memorandum of Understanding (MOU) for Global ARDS License with Healios
- Athersys Licenses its Animal Health Assets to Ardent Animal Health
Your note
Sign in to keep a note on ATHX — it syncs with the Stock Master app.